The relationship between pathological brain activity and functional network connectivity in glioma patients
ConclusionOur results indicate that pathological activity and connectivity co-localize in a complex manner in glioma. This insight is relevant to our understanding of disease progression and cognitive symptomatology. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 3, 2024 Category: Cancer & Oncology Source Type: research

Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study
ConclusionsThe accuracy of online target contouring was unsatisfactory for the current MRI-guided online adaptive FSRT. Small lesions had poor visibility on 1.5  T non-contrast-enhanced MR-Linac images. Contour inaccuracies caused a one-third drop in prescription dose coverage for the target volume. Future studies should explore the feasibility of contrast agent administration during daily treatment in MRI-guided online adaptive FSRT procedures. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 1, 2024 Category: Cancer & Oncology Source Type: research

Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline
ConclusionAutomated detection and volumetric quantification of brain metastases following SRS have the potential to enhance the assessment of treatment response and alleviate the clinician workload. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - February 1, 2024 Category: Cancer & Oncology Source Type: research

An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma
ConclusionPreoperative Bev and TMZ is safe as long as the instructions are followed. The strategy might be useful for GB in some patients, not only reducing tumor burden, but also improving patient KPS preoperatively.Trial Registration Number: UMIN000025579, jRCT1031180233https://jrct.niph.go.jp/latest-detail/jRCT1031180233. Registration Date: Jan. 16, 2017 (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research

Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review
ConclusionLMD continues to be an uncommon complication associated with HGG with a poor prognosis. This article provides an overview of the presently available literature on IT chemotherapy for LMD secondary to HGG, and their respective treatment protocols with overall survival attributes. Additional research is warranted to ascertain how to maximize the potential efficacy of IT chemotherapy as a treatment option. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research

The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review
ConclusionsThis review highlights areas of uncertainty in this research area. A well-defined, well-funded research agenda is needed to best maximise the potential of PBT.Systematic review registration.PROSPERO-CRD42016036802. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 31, 2024 Category: Cancer & Oncology Source Type: research

Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 30, 2024 Category: Cancer & Oncology Source Type: research

Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma
ConclusionIn this study we found that the use of rivaroxaban was associated with more bleeding-related events compared to apixaban and enoxaparin in patients with high-grade glioma. In this study we also found that the diagnosis of astrocytoma, IDH mutant, grade 4 was associated with more bleeding events. However, this is based on a small study and there is a need for larger studies to further evaluate these results. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research

Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial
ConclusionsThis study analyzes iron-related biomarkers in the context of P-AscH− therapy for glioblastoma. Integrating molecular, systemic, and imaging-based markers offers a multifaceted approach to tailoring treatment strategies, thereby contributing to improved patient outcomes and advancing the field of glioblastoma therapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research

Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting
ConclusionCurrent notable interlaboratory variations as illustrated in this study should be reduced in order to refine diagnostics and improve precision oncology. In-house developed tests, standardized panels and routine application of broad gene panels all have their own advantages and disadvantages. Future research would be of interest to study the clinical impact of variation in diagnostic approaches. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research

GammaTile ® (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials
ConclusionOur pilot experience suggests that GT offers favorable local control and safety profile for patients afflicted with rapidly proliferating glioblastomas and lay the foundation for future clinical trial design. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 28, 2024 Category: Cancer & Oncology Source Type: research

Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma
ConclusionWe conclude that chemotherapy with TMZ can be dramatically enhanced by delivering at the daily maximum of tumor Bmal1 expression and minimum of MGMT activity and that scoring MGMT methylation status requires controlling for time of day of biopsy.Graphical abstract (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 26, 2024 Category: Cancer & Oncology Source Type: research

CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization
ConclusionsCDKN2A/B-deletion was observed across all the histological grades ofIDH-mutant astrocytic tumours, expectedly more in the higher grade. FISH, as a method, can be used for the detection ofCDKN2A/B homozygous deletion, when there is concordant interpretation. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 24, 2024 Category: Cancer & Oncology Source Type: research

Adjuvant convection-enhanced delivery for the treatment of brain tumors
ConclusionEfficacy of CED for malignant glioma to date has been mixed, but improvements in technology and therapeutic agents arepromising. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 23, 2024 Category: Cancer & Oncology Source Type: research

Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide
ConclusionTargeting AG4 with EGFR BATs at the maximum feasible dose of 80  × 109, with or without TMZ was safe and induced significant anti-tumor-specific immune responses. These results support further clinical trials to examine the efficacy of this adoptive cell therapy in patients with MGMT-unmethylated GBM.ClinicalTrials.gov Identifier: NCT03344250 (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 23, 2024 Category: Cancer & Oncology Source Type: research